27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Vaxart Inc (NASDAQ:VXRT) is trading higher Monday morning after the company announced the U.S. Food and Drug Administration cleared its Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate.
"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial," said Andrei Floroiu, CEO of Vaxart.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.
Vaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.
Price Action: Vaxart has traded as high as $24.90 and as low as $3.50 over a 52-week period.
At last check Monday, the stock was up 13.60% at $8.17.
See also: BEST MEDICARE PRESCRIPTION DRUG PLANS
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.